Who we are

Alopecia Areata: The shame and embarrassment of this disease devastates the lives of too many women and girls when treatments do not work. Since 2007 Bald Girls Do Lunch has connected with over 3,000 to restore self-confidence and conquer isolation. With requests for meet-ups in every state and beyond the USA, Bald Girls is answering the plea for women to find others for community and support. From intimate groups to style workshops to restoring her looks, BGDL puts women on the track to normalcy and living well with this disease. Learn more...

BGDL Facebook Page


Little Rock, Arkansas Event: April 29

March 17th, 2018 by Chassin

Bald is Beautiful in Arkansas

Got alopecia? Join Bald Girls Do Lunch CEO, Thea Chassin, for friendship, camaraderie and her Live Well with Alopecia™ Spring 2018 tips.

  • • Meet locals like yourself who understand the challenges of alopecia.
  • • Get answers to questions about living with alopecia and treatment regimens.
  • • Need eyebrow help? We’ve got you covered with our BGBrows demo.
  • • Be comfy. Be yourself. We love all options: wear your wigs, hair, hats or bald look.

Register Here

Alopecia Areata Research Update from Mount Sinai

August 9th, 2016 by Chassin

Guttamn Staff
Dept of Dermatology Researchers, Icahn School of Medicine, Mount Sinai Health System

Here at Mount Sinai School of Medicine, it is an exciting time for treatment in alopecia areata. Currently we have three trials going on: an injectable, a topical and an oral. Read More

Read More

Clinical Trials Underway at Mount Sinai Department of Dermatology

March 18th, 2016 by Chassin

Icahn School of Medicine at Mount Sinai (New York)

Alopecia Areata research is of great interest to people with this autoimmune skin disorder. This Bald Girls Do Lunch blog informs you with patient-friendly posts on alopecia areata news, clinical trials and popular posts like our features on Tofacitinib and Ruxolitinib. In 2016…Read More

Read More

6 Questions for Xeljanz Trial Participant

August 21st, 2015 by Chassin


6 Questions for Alopecia Patient on Xeljanz http://bgdl.org/1Jqgj0J

Alopecia areata patient on Xeljanz talks to Bald Girls Do Lunch alopecia support founder Thea Chassin.

FDA Hearings to Include Alopecia Areata

July 14th, 2015 by Chassin


Alopecia Areata Slated for FDA Hearings http://bgdl.org/1LeuyGa

Bald Girls Do Lunch Announces FDA Hearings on #AlopeciaAreata #alopecia

Physicians Note That Alopecia Drug Treatments Require Further Testing

October 9th, 2014 by Chassin



When headlines hit the media with word combinations like alopecia, research, clinical trials and drugs, we want to help you understand them and keep them in perspective.


Read the full article here:

Physicians Note That Alopecia Drug Treatments Require Further Testing


Sign up for weekly updates here.


Lumigan is a hot topic – but not for AA, yet.

December 4th, 2008 by Chassin

 It was announced in a press release by Allergan Inc. on 12/3/08 that the drug Lumigan, currently approved to treat glaucoma, is close to FDA approval for cosmetic use as an eyelash growth enhancer for upper lashes – but don’t get excited if you have extensive loss due to AA. It had been discovered in clinical studies that a side effect in glaucoma patients was the growth of longer, darker and fuller lashes. The FDA posted a review of the drug on its Web site Wednesday ahead of a Friday review by an outside panel of medical experts. The advisory panel is being asked to vote on whether it thinks Latisse ( the proposed brand name) should be approved. The FDA usually follows its panels’ advice. If approved, the product would be the first FDA-approved product sold for eyelash enhancement.

Two pilot studies were done with alopecia areata volunteers at the  University of California San Francisco using Lumigan or Xalatan on patients with greater than 50 percent eyelash loss and concluded that it was not effective. No study has yet been done on AA patients with less than 50 percent loss. These pilot studies were a joint effort of the UCSF departments of dermatology and opthalmology with principal investigators Drs. Price and Stamper.

And as with all drugs, there will be risks and the potential for serious side effects in some people.

Click here for FDA briefing documents.